The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
Publications
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 Jul 12;;10781552221114070 — 2022 Jul 12 — 10781552221114070
Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.
Clinical case reports 2021 May;9;e03164 — 2021 May — e03164
Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
American journal of hematology 2014 Jul;89;732-42 — 2014 Jul — 732-42
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Therapeutic advances in hematology 2014 Feb;5;13-7 — 2014 Feb — 13-7
Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood 2011 Oct 27;118;4567-76 — 2011 Oct 27 — 4567-76